FINDINGS High-Risk Factor: Off-Label Use Of Clotting Drug

摘要

An expensive clotting drug approved to treat only hemophilia has become extremely popular in hospitals to stem bleeding during heart surgery, brain hemorrhages, trauma, liver transplants, and prostate removal. A massive new analysis drawing on 64 studies of these "off-label" uses of the drug, recom-binant factor Vila (rFVIIa), found no evidence that it prolonged life; in some cases, it caused dangerous embolisms.